Saturday 17 October 2026
Export TMDX’s income statement to Excel — free account
TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.7%, EPS fell 59.2%, free cash flow fell 87.6% and total debt rose 68.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
70.78
5.74
−7.50%
Follow TMDX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
41.56 | 21.80 | 19.76 | 15.03 |
P/S ratio |
6.76 | 6.83 | 5.38 | 3.44 | |
P/FCF ratio |
31.72 | 30.96 | 22.58 | 29.06 | |
P/Operating CF |
55.01 | 119.82 | 139.33 | 132.69 | |
P/B ratio |
10.78 | 8.74 | 6.92 | 4.43 | |
Price to Tangible BV |
11.20 | 9.00 | 7.08 | 4.53 | |
EV/Sales |
6.84 | 6.87 | 6.00 | 4.02 | |
EV/EBITDA |
31.91 | 30.64 | 29.94 | 22.76 | |
EV/Operating CF |
21.76 | 21.57 | 17.32 | 18.40 | |
EV/FCF |
32.10 | 31.14 | 25.19 | 33.98 | |
Quick Ratio |
6.86 | 6.41 | 6.01 | 5.87 | |
Current Ratio |
7.69 | 7.14 | 6.74 | 6.63 | |
Net Debt/EBITDA |
1.51 | 0.84 | 15.71 | 11.45 | |
Debt/Assets |
54.09% | 47.96% | 59.73% | 58.84% | |
Debt/Equity |
1.44 | 1.08 | 1.73 | 1.66 | |
Asset Turnover |
0.65 | 0.65 | 0.56 | 0.57 | |
Operating CF/Net income |
2.86 | 0.33 | 3.35 | 1.18 | |
Capex/Depreciation |
(1.11) | (2.08) | (3.09) | (0.69) | |
Interest Coverage |
6.67 | 6.34 | 1.85 | 3.29 | |
Research and Development Expense of Revenue |
10.61% | 12.88% | 14.30% | 16.65% | |
Selling, General and Administrative Expense of Revenue |
31.99% | 32.00% | 36.21% | 30.45% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
6.35% | 5.84% | 5.72% | 4.53% | |
Graham Net Nets |
0.01 | 0.01 | (0.09) | (0.13) | |
Graham Number |
25.15 | 41.80 | 40.32 | 38.60 | |
Earnings Yield |
2.41% | 4.59% | 5.06% | 6.65% | |
Free Cash Flow Yield |
3.15% | 3.23% | 4.43% | 3.44% | |
Revenue per Share |
4.22 | 4.73 | 5.06 | 5.49 | |
Operating CF per Share |
2.04 | 1.02 | 0.71 | 0.50 | |
Capex per Share |
(0.22) | (0.46) | (1.07) | (0.21) | |
Free Cash Flow per Share |
1.82 | 0.56 | (0.35) | 0.30 | |
Cash per Share |
13.67 | 14.37 | 13.43 | 13.67 | |
Shareholders Equity per Share |
10.41 | 13.92 | 14.37 | 14.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.41 | 13.92 | 14.37 | 14.98 | |
Free Cash Flow |
61.95 | 19.00 | (12.12) | 10.22 | |
Working Capital |
533.28 | 548.48 | 527.36 | 552.84 | |
Capital Expenditures |
(7.62) | (15.51) | (36.66) | (7.09) | |
Net Current Asset Value |
22.16 | 42.51 | (321.53) | (295.22) | |
EV/EBIT |
40.36 | 38.31 | 40.38 | 32.91 | |
Capex to Sales |
0.05 | 0.10 | 0.21 | 0.04 | |
Price to Operating Income |
39.89 | 38.08 | 36.19 | 28.15 | |
| Other line items | |||||
Average Receivables |
85.42 | 91.00 | 116.38 | 104.49 | |
Average Payables |
12.65 | 10.32 | 10.87 | 11.22 | |
Average Inventory |
48.33 | 47.72 | 46.64 | 46.50 | |
Average Assets |
865.80 | 936.22 | 1,136.18 | 1,177.46 | |
Average Common Equity |
282.56 | 350.85 | 380.16 | 418.08 |
Columns are period end dates